Antoni Ribas

Trials

Studies that name Antoni Ribas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:28 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07463365 · LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults

  Antoni Ribas · not yet recruiting · Venous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLU · study director
• Ph1
  NCT07463378 · Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults

  Antoni Ribas · not yet recruiting · Wound Healing, Acute Skin Wounds · study director
• Ph1
  NCT04119024 · Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  Anusha Kalbasi · recruiting · Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · principal investigator
• Ph1
  NCT03425461 · Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

  Jonsson Comprehensive Cancer Center · terminated · Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 · principal investigator
• N/A
  NCT03409419 · PET Imaging of the Immune System Using Analog Probes

  Jonsson Comprehensive Cancer Center · completed · Malignant Melanoma · principal investigator
• Ph1
  NCT02775292 · Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

  Jonsson Comprehensive Cancer Center · completed · Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm · principal investigator
• Ph1/Ph2
  NCT02521870 · A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  Dynavax Technologies Corporation · terminated · Metastatic Melanoma, Head Neck Cancer · principal investigator
• Ph2
  NCT02263898 · Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

  Jonsson Comprehensive Cancer Center · withdrawn · Recurrent Melanoma, Stage IV Melanoma · principal investigator
• Ph1
  NCT02070406 · Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

  Jonsson Comprehensive Cancer Center · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
• Ph1/Ph2
  NCT01902173 · Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

  National Cancer Institute (NCI) · completed · Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma · principal investigator
• Ph2
  NCT00910650 · Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

  Jonsson Comprehensive Cancer Center · completed · Metastatic Melanoma · principal investigator
• Ph1
  NCT00689065 · Safety Study of CALAA-01 to Treat Solid Tumor Cancers

  Calando Pharmaceuticals · terminated · Cancer, Solid Tumor · principal investigator
• Ph2
  NCT00471887 · Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

  Jonsson Comprehensive Cancer Center · completed · Melanoma (Skin) · principal investigator
• Ph2
  NCT00107159 · Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

  Jonsson Comprehensive Cancer Center · completed · Melanoma (Skin) · study chair
• Ph2
  NCT00099970 · Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

  PDL BioPharma, Inc. · completed · Melanoma, Metastases · principal investigator
• Ph1/Ph2
  NCT00093548 · Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer

  Jonsson Comprehensive Cancer Center · withdrawn · Liver Cancer · study chair
• Ph1
  NCT00090896 · CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

  Jonsson Comprehensive Cancer Center · completed · Melanoma (Skin) · study chair
• Ph2
  NCT00081042 · ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

  Jonsson Comprehensive Cancer Center · completed · Melanoma (Skin) · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Next Generation Cancer Immunotherapies to Defeat Melanoma
  R35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2015 to 2026 · $936,000 awarded in 2026
  Grant number is on one of their registry trials
• Tumor Immunology and Immunotherapy (TII)
  P30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2020 to 2026 · $83,267 awarded in 2026
  Grant number is on one of their registry trials
• Administrative and Statistics Core
  P01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2020 to 2024 · $301,342 awarded in 2024
  Same name and institution; not confirmed by an ID
• Overcoming BRAF-inhibitor Resistance in Melanoma
  P01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2013 to 2017 · $1,688,850 awarded in 2017
  Grant number is on one of their registry trials
• Response and Acquired Resistance to PD-1 Blockade
  R01CA199205 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2015 · $551,291 awarded in 2015
  Same name and institution; not confirmed by an ID
• Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
  R01CA170689 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · fiscal years 2012 to 2015 · $626,768 awarded in 2015
  Same name and institution; not confirmed by an ID
• Cell and Gene Therapy, Clinical Manufacture and Monitoring Core
  P01CA132681 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · fiscal years 2010 to 2014 · $484,169 awarded in 2014
  Same name and institution; not confirmed by an ID
• Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...
  P50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2005 to 2014 · $217,272 awarded in 2014
  Same name and institution; not confirmed by an ID
• Academic Training in Medical Oncology
  T32CA009297 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2009 to 2013 · $65,267 awarded in 2013
  Same name and institution; not confirmed by an ID
• ADOPTIVE TRANSFER OF MART-1 F5 TCR ENGINEERED PERIPHERAL BLOOD MONONUCLEAR CELLS
  M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2004 to 2010 · $13,844 awarded in 2010
  Same name and institution; not confirmed by an ID
• AFP-Based Immunotherapy for Hepatocellular Carcinoma
  K23CA093376 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2002 to 2006 · $126,880 awarded in 2006
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Pediatric Scientist Development Program
  K12HD000850 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI Sallie R. Permar · fiscal years 1987 to 2026
  Named on NCT02775292
• NCI NCTN- Network Lead Academic Participating Site: USC
  U10CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Anthony Boutros El-Khoueiry, HEINZ JOSEF LENZ, DAVID IAN QUINN · fiscal years 2014 to 2018
  Named on NCT01902173
• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT01902173
• Southwest Oncology Group Treatment Grant
  U10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013
  Named on NCT01902173